- Home
- OCCI vs BDTX Comparison
OCCI vs BDTX Comparison
Compare OCCI & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCCI
- BDTX
- Stock Information
- Founded
- OCCI N/A
- BDTX 2014
- Country
- OCCI United States
- BDTX United States
- Employees
- OCCI N/A
- BDTX N/A
- Industry
- OCCI Trusts Except Educational Religious and Charitable
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OCCI Finance
- BDTX Health Care
- Exchange
- OCCI Nasdaq
- BDTX Nasdaq
- Market Cap
- OCCI 152.2M
- BDTX 181.4M
- IPO Year
- OCCI N/A
- BDTX 2020
- Fundamental
- Price
- OCCI $5.54
- BDTX $3.89
- Analyst Decision
- OCCI
- BDTX Strong Buy
- Analyst Count
- OCCI 0
- BDTX 5
- Target Price
- OCCI N/A
- BDTX $12.00
- AVG Volume (30 Days)
- OCCI 115.8K
- BDTX 1.1M
- Earning Date
- OCCI 12-11-2023
- BDTX 11-04-2025
- Dividend Yield
- OCCI 24.32%
- BDTX N/A
- EPS Growth
- OCCI N/A
- BDTX N/A
- EPS
- OCCI N/A
- BDTX 0.25
- Revenue
- OCCI N/A
- BDTX $70,000,000.00
- Revenue This Year
- OCCI N/A
- BDTX N/A
- Revenue Next Year
- OCCI $10.19
- BDTX N/A
- P/E Ratio
- OCCI N/A
- BDTX $15.54
- Revenue Growth
- OCCI N/A
- BDTX N/A
- 52 Week Low
- OCCI $5.47
- BDTX $1.20
- 52 Week High
- OCCI $10.15
- BDTX $3.99
- Technical
- Relative Strength Index (RSI)
- OCCI 43.06
- BDTX 68.80
- Support Level
- OCCI $5.36
- BDTX $3.62
- Resistance Level
- OCCI $5.54
- BDTX $3.87
- Average True Range (ATR)
- OCCI 0.15
- BDTX 0.20
- MACD
- OCCI -0.01
- BDTX 0.05
- Stochastic Oscillator
- OCCI 40.24
- BDTX 98.88
About OCCI OFS Credit Company Inc.
OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation through investment in collateralized loan obligation (CLO) equity and debt securities. The company invests in floating rate credit instruments and other structured credit investments, including; collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.